Pharmaceutical Formulation Scientists are integral to the drug development process, specializing in creating drug products that are both effective and safe for patient use. They focus on transforming active pharmaceutical ingredients (APIs) into practical, stable, and reliable dosage forms, such as tablets, capsules, injectables, or topical creams. Their expertise involves understanding the physicochemical properties of both the drug and excipients to design formulations that optimize bioavailability, stability, and controlled release. This is essential to ensuring that the drug performs as intended once administered to the patient, maintaining therapeutic efficacy over its shelf life. Their work is vital to the development of new therapies, ensuring that the drug product remains consistent and effective across all stages of production and usage.
These scientists work collaboratively with teams from various disciplines, including regulatory affairs, analytical chemistry, and manufacturing, to develop formulations that meet rigorous safety and quality standards. They are responsible for conducting pre-formulation studies, stability testing, and compatibility studies to determine the best formulation strategies for a given drug. Furthermore, they also play a critical role in scaling up drug production, ensuring that formulations maintain their quality at large manufacturing volumes. As the pharmaceutical landscape evolves, pharmaceutical formulation scientists are at the forefront of developing innovative drug delivery systems, including biologics, vaccines, and personalized medicines, ultimately improving patient care and the success of new therapeutic products.
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through design-inspired biotech- & biopharma-driven applications and upgraded business marketing to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Genetic keys and nano locks: Unlocking personalized medicine
Srividya Narayanan, Northeastern University, United States
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico